LIGHT Trial: Levothyroxine for Gestational Hypothyroidism in Recurrent Pregnancy Loss

Launched by WOMEN'S HOSPITAL SCHOOL OF MEDICINE ZHEJIANG UNIVERSITY · May 30, 2025

Keywords

ClinConnect Summary

The LIGHT Trial is a research study designed to see if taking levothyroxine, a medication used to treat low thyroid hormone levels, can help improve pregnancy outcomes for women who have experienced multiple miscarriages and have isolated maternal hypothyroidism (a condition where thyroid hormone levels are low but other thyroid tests are normal). The main goal is to find out if this treatment can increase the chances of having a healthy baby after 24 weeks of pregnancy and if it can reduce the risk of pregnancy loss or other complications.

To participate in this trial, women must be pregnant with one baby and have a history of having two or more miscarriages before 20 weeks. They also need to have been diagnosed with low thyroid hormone levels in their current pregnancy. If eligible, participants will be randomly assigned to either receive levothyroxine or a placebo (a pill with no active medication) and will take their assigned treatment daily until the pregnancy ends. They will have regular check-ups to monitor their pregnancy progress. This trial is important because it could provide valuable information about how levothyroxine might help women with these specific challenges during pregnancy.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • women with singleton pregnancy
• • women with a history of recurrent pregnancy loss (defined as two or more pregnancy loss before 20wks)
• • women diagnosed with isolated maternal hypothyroidism (defined as isolated lower level of FT4 with normal TSH levels) in the current pregnancy before 20wks
• Exclusion Criteria:
• • patients with known thyroid disorders
• • patients with antiphospholipid syndrome or other autoimmune conditions
• • patients with contraindications to levothyroxine (e.g., acute cardiac arrest, acute pancreatitis, acute myocarditis)
• • patients attending other ongoing clinical trials or unwilling to participate.